Status:
UNKNOWN
Loop Gain in the Reversion of OSA Treated by Either CPAP or Cardiac Valve Replacement
Lead Sponsor:
Nanjing Medical University
Conditions:
Obstructive Sleep Apnea of Adult
Heart Valve Diseases
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Sleep apnea including obstructive sleep apnea (OSA) and central sleep apnea (CSA), are common in patients with cardiovascular disease. The prevalence of OSA is 2%-4% in general population and 16%-47% ...
Detailed Description
Between January 31, 2020 and June 30, 2023, 300 patients with valvular heart disease waiting for cardiac valve replacement in Department of Cardiovascular Surgery were screened for obstructive sleep a...
Eligibility Criteria
Inclusion
- Patients aged 18-75 years.
- Patients with heart valve disease.
- Patients combined with obstructive sleep apnea (apnea-hypopnea index \>=5/h).
- Received cardiac valve replacement surgery.
- The enrolled patients having received patients' informed consent.
Exclusion
- History of stroke or clinical signs of peripheral or central nervous system disorders.
- History of chronic obstructive pulmonary disease or asthma.
- Enrolment in another clinical study.
Key Trial Info
Start Date :
January 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03839654
Start Date
January 31 2020
End Date
December 31 2023
Last Update
March 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029